Upcoming events on REGENERON PHARMACEUTICALS |
|
02/05/21 | | FY 2020 Earnings Release |
02/05/21 | 08:30am | | FY 2020 Earnings Call |
05/06/21 | | Q1 2021 Earnings Release (Projected) |
08/05/21 | | Interim 2021 Earnings Release (Projected) |
|
Past events on REGENERON PHARMACEUTICALS |
|
01/11/21 | 08:20am | | JP Morgan Healthcare Conference |
12/07/20 | 04:30pm | | American Society of Hematology Meeting |
12/02/20 | 08:00am | | Piper Sandler Health Care Conference |
12/01/20 | 10:30am | | Evercore ISI HealthCONx Conference |
|
Upcoming sector events for REGENERON PHARMACEUTICALS |
|
|
|
Past sector events for REGENERON PHARMACEUTICALS |
|
|
|
Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales M $ |
Released Forecast Spread | 4 104 4 177 -1,8% | 4 860 4 923 -1,3% | 5 872 5 788 1,5% | 6 711 6 520 2,9% | 7 863 7 816 0,61% | 8 494
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 1 327 1 501 -12% | 1 435 1 470 -2,3% | 2 732 2 658 2,8% | 3 110 2 959 5,1% | 3 420 3 610 -5,3% | 4 158
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 252 1 392 -10% | 1 331 1 351 -1,5% | 2 080 2 094 -0,70% | 2 534 2 424 4,5% | 2 210 2 285 -3,3% | 3 483
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 1 225 1 369 -11% | 1 330 1 357 -2,0% | 2 079 2 075 0,16% | 2 554 2 543 0,39% | 2 429 2 308 5,3% | 3 586
|
Net income M $ |
Released Forecast Spread | 636 680 -6,5% | 896 894 0,12% | 1 199 1 438 -17% | 2 444 2 257 8,3% | 2 116 1 998 5,9% | 3 172
|
EPS $ |
Released Forecast Spread | 5,52 5,95 -7,2% | 7,70 7,66 0,51% | 10,3 12,6 -18% | 21,3 19,7 7,9% | 18,5 17,6 4,7% | 28,0
| Announcement Date | 02/09/2016 | 02/09/2017 | 02/08/2018 | 02/06/2019 | 02/06/2020 | |
|
|
Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales M $ |
Released Forecast Spread | 1 608 1 565 2,7% | 1 663 1 637 1,6% | 1 928 1 729 12% | 1 712 1 763 -2,9% | 1 934 1 802 7,3% | 2 048 1 982 3,4% | 2 170 2 101 3,2% | 1 828 1 811 0,96% | 1 952 1 746 12% | 2 294 2 085 10% | 2 405
| 2 449
| 2 981
| 2 765
| 2 814
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 763 663 15% | 774 617 25% | 888 622 43% | 644 780 -17% | 879 720 22% | 909 888 2,4% | 989 933 5,9% | 756 867 -13% | 715 890 -20% | 1 112 907 23% | 1 194
| 913
| 903
| 1 078
| 951
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 622 577 7,8% | 627 591 6,1% | 718 611 18% | 480 637 -25% | 316 162 95% | 739 757 -2,4% | 676 781 -13% | 700 747 -6,3% | 656 714 -8,1% | 1 053 850 24% | 1 027
| 1 062
| 1 099
| 1 137
| 1 158
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 656 580 13% | 636 611 4,1% | 676 621 8,9% | 546 642 -15% | 225 197 14% | 769 730 5,2% | 890 795 12% | 669 770 -13% | 919 707 30% | 998 861 16% | 885
| 1 044
| 1 065
| 1 105
| 1 047
|
Net income M $ |
Released Forecast Spread | 551 468 18% | 595 509 17% | 820 590 39% | 461 535 -14% | 193 169 14% | 670 643 4,1% | 792 682 16% | 625 630 -0,93% | 897 596 51% | 842 713 18% | 799
| 958
| 1 094
| 951
| 935
|
EPS $ |
Released Forecast Spread | 4,82 4,02 20% | 5,17 4,43 17% | 7,15 5,32 34% | 3,99 4,63 -14% | 1,68 1,40 20% | 5,86 5,69 2,9% | 6,93 6,18 12% | 5,43 5,50 -1,3% | 7,61 5,07 50% | 7,39 6,35 16% | 7,10
| 9,47
| 13,0
| 9,38
| 9,24
| Announcement Date | 08/02/2018 | 11/06/2018 | 02/06/2019 | 05/07/2019 | 08/06/2019 | 11/05/2019 | 02/06/2020 | 05/05/2020 | 08/05/2020 | 11/05/2020 | | | | | |
|
Financial data source © 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|